Magenta Therapeutics, Inc.

MGTA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$37-$32-$30-$32
Dep. & Amort.$0$0$0-$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$6$6$5$10
Change in WC$0$0$0$19
Other Non-Cash$0$2-$4-$16
Operating Cash Flow-$31-$24-$28-$19
Investing Activities
PP&E Inv.-$0-$0-$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$280-$33-$67-$394
Inv. Sales/Matur.$79$60$82$52
Other Inv. Act.$0$0$0-$6
Investing Cash Flow-$201$26$15-$347
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$36
Stock Repurch.$0$0$0-$50
Dividends Paid$0$0$0$0
Other Fin. Act.$275$1$0$206
Financing Cash Flow$275$1$0$206
Forex Effect$0$0$0$12
Net Chg. in Cash$43$3-$13-$40
Supplemental Information
Beg. Cash$13$10$23$63
End Cash$56$13$10$23
Free Cash Flow-$31-$24-$28-$19
Magenta Therapeutics, Inc. (MGTA) Financial Statements & Key Stats | AlphaPilot